BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 186 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $24,365,000 | +11670.5% | 161,174 | +11250.3% | 2.23% | +12300.0% |
Q2 2022 | $207,000 | -55.7% | 1,420 | -70.5% | 0.02% | -60.0% |
Q2 2021 | $467,000 | -49.2% | 4,808 | -61.8% | 0.04% | -57.5% |
Q2 2020 | $919,000 | +242.9% | 12,573 | +95.9% | 0.11% | +404.8% |
Q3 2019 | $268,000 | – | 6,419 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |